Circulatory Panel Warms To Cardiac Freezor Despite Missed Trial Targets
This article was originally published in The Gray Sheet
Executive Summary
CryoCath Technologies' Freezor is approvable, with conditions, for cardiac cryoablation despite failing to meet pre-determined safety and efficacy endpoints, FDA's Circulatory System Devices Panel concluded in a 7-3 vote March 6 in Gaithersburg, Md
You may also be interested in...
EP Studies Should Return To Basics, FDA Says; CRT Trial Endpoints Assessed
CDRH Division of Cardiovascular Devices Director Bram Zuckerman is warning manufacturers of an over-reliance on surrogate endpoints that the agency has observed in electrophysiology device trials
EP Studies Should Return To Basics, FDA Says; CRT Trial Endpoints Assessed
CDRH Division of Cardiovascular Devices Director Bram Zuckerman is warning manufacturers of an over-reliance on surrogate endpoints that the agency has observed in electrophysiology device trials
CryoCath Freezor Tachycardia Approval Includes Cryomapping Indication
CryoCath says it will pursue an expanded indication for its Freezor cardiac cryoablation system to address epicardial posteroseptal accessory atrioventricular pathways